Genetically engineered bacteria as inflammatory bowel disease therapeutics

Abstract

Inflammatory bowel disease (IBD) is a chronic and recurrent disease caused by immune response disorders that disrupt the intestinal lumen symbiotic ecosystem and dysregulate mucosal immune functions. Current therapies available for IBD primarily focus on symptom management, making early diagnosis and prompt intervention challenging. The development of genetically engineered bacteria using synthetic biology presents a new strategy for addressing these challenges. In this review, we present recent breakthroughs in the field of engineered bacteria for the treatment and detection of IBD and describe how bacteria can be genetically modified to produce therapeutic molecules or execute diagnostic functions. In particular, we discuss the challenges faced in translating live bacterial therapeutics from bacterial design to delivery strategies for further clinical applications.

Keywords

Genetically engineered bacteria / Inflammatory bowel disease / Bacterial therapeutics

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

CRediT authorship contribution statement

Zhen-Ping Zou: Writing - original draft, Conceptualization. Xiao-Peng Zhang: Writing - original draft. Qian Zhang: Writing - review & editing. Bin-Cheng Yin: Writing - review & editing. Ying Zhou: Writing - review & editing, Writing - original draft, Funding acquisition. Bang-Ce Ye: Writing - review & editing, Conceptualization.

Acknowledgments

This work was sponsored by the National Key Research and Development Program of China (2023YFF1204500), the National Natural Science Foundation of China (22134003), and China Postdoctoral Science Foundation (2023M741176).

References

[1] G.G. Kaplan, J.W. Windsor, The four epidemiological stages in the global evolution of inflammatory bowel disease, Nat. Rev. Gastroenterol. Hepatol. 18 (2021) 56-66, doi:10.1038/s41575-020-00360-x.

[2] L.P. Bruner, A.M. White, S. Proksell, Inflammatory Bowel Disease, Prim. Care 50 (2023) 411-427, doi:10.1016/j.pop.2023.03.009.

[3] H.H. Uhlig, F. Powrie, Translating Immunology into Therapeutic Concepts for Inflammatory Bowel Disease, Annu. Rev. Immunol. 36 (2018) 755-781, doi:10.1146/annurev-immunol-042617-053055.

[4] S.C. Ng, Emerging Trends of Inflammatory Bowel Disease in Asia, Gastroenterol. Hepatol. 12 (2016) 193-196.

[5] Y. Chen, G. Zhang, Y. Yang, S. Zhang, H. Jiang, K. Tian, D.Chen Arenbaoligao, The treatment of inflammatory bowel disease with monoclonal antibodies in Asia, Biomed. Pharmacother. 157 (2023) 114081, doi:10.1016/j.biopha.2022.114081.

[6] T. Zenlea, M.A. Peppercorn, Immunosuppressive therapies for inflam- matory bowel disease, World J. Gastroenterol. 20 (2014) 3146-3152, doi:10.3748/wjg.v20.i12.3146.

[7] M. Barra, T. Danino, D. Garrido, Engineered Probiotics for Detection and Treat- ment of Inflammatory Intestinal Diseases, Front. Bioeng. Biotechnol. 8 (2020) 265, doi:10.3389/fbioe.2020.00265.

[8] J.E. Baars, E.J. Kuipers, M. van Haastert, J.J. Nicolaï, A.C. Poen, C.J. van der Woude, Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey, J. Gastroenterol. 47 (2012) 1308-1322, doi:10.1007/s00535-012-0603-2.

[9] V. Annese, L. Beaugerie, L. Egan, L. Biancone, C. Bolling, C. Brandts, D. Dierickx, R. Dummer, G. Fiorino, J.M. Gornet, P. Higgins, K.H. Katsanos, L. Nissen, G. Pellino, G. Rogler, F. Scaldaferri, E. Szymanska, R. Eliakim, European Evidence-based Con- sensus: Inflammatory Bowel Disease and Malignancies, J. Crohns Colitis 9 (2015) 945-965, doi:10.1093/ecco-jcc/jjv141.

[10] K.D. Clark-Snustad, S.D. Lee, Diagnosing inflammatory bowel disease and differen- tiating it from potential mimics, Tech. Gastrointest. Endosc. 18 (2016) 108-115, doi:10.1016/j.tgie.2016.07.006.

[11] N. Plevris, C.W. Lees, Disease Monitoring in Inflammatory Bowel Disease: Evolv- ing Principles and Possibilities, Gastroenterology 162 (2022) 1456-1475 e1451, doi:10.1053/j.gastro.2022.01.024.

[12] T. Yamamoto, The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn’s disease, United, European Gastroenterol. J. 3 (2015) 5-10, doi:10.1177/2050640614558106.

[13] E. Burri, C. Beglinger, The use of fecal calprotectin as a biomarker in gas- trointestinal disease, Expert Rev. Gastroenterol. Hepatol. 8 (2014) 197-210, doi:10.1586/17474124.2014.869476.

[14] K. Kalantar-Zadeh, K.J. Berean, N. Ha, A.F. Chrimes, K. Xu, D. Grando, J.Z. Ou, N. Pillai, J.L. Campbell, R. Brklja ča, K.M. Taylor, R.E. Burgell, C.K. Yao, S.A. Ward, C.S. McSweeney, J.G. Muir, P.R. Gibson, A human pilot trial of ingestible electronic capsules capable of sensing different gases in the gut, Nat. Electron. 1 (2018) 79-87, doi:10.1038/s41928-017-0004-x.

[15] Q. Ren, S. Sun, X.-D. Zhang, Redox-active nanoparticles for inflammatory bowel disease, Nano Res. 14 (2021) 2535-2557, doi:10.1007/s12274-021-3303-5.

[16] I.M. Balmus, A. Ciobica, A. Trifan, C. Stanciu, The Implications of Oxidative Stress and Antioxidant Therapies in Inflammatory Bowel Disease: Clinical Aspects and Animal Models, Saudi J. Gastroenterol. 22 (2016), doi:10.4103/1319-3767. 173753.

[17] H. Zhu, Y.R. Li, Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence, Exp. Biol. Med. 237 (2012) 474-480, doi:10.1258/ebm.2011.011358.

[18] S. Binda, C. Hill, E. Johansen, D. Obis, B. Pot, M.E. Sanders, A. Tremblay, A. C. Ouwehand, Criteria to Qualify Microorganisms as "Probiotic" in Foods and Dietary Supplements, Front, Microbiol 11 (2020), doi:10.3389/fmicb.2020.01662.

[19] A. Oka, R.B. Sartor, Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases, Dig. Dis. Sci. 65 (2020) 757-788, doi:10.1007/s10620-020-06090-z.

[20] C. Mazziotta, M. Tognon, F. Martini, E. Torreggiani, J.C. Rotondo, Probiotics Mech- anism of Action on Immune Cells and Beneficial Effects on Human Health, Cells DOI (2023) 12, doi:10.3390/cells12010184.

[21] L.A.A.P. Derikx, L.A. Dieleman, F. Hoentjen, Probiotics and prebiotics in ulcerative colitis, Best Pract. Res. Clin. Gastroenterol. 30 (2016) 55-71, doi:10.1016/j.bpg.2016.02.005.

[22] S. Zhou, C. Gravekamp, D. Bermudes, K. Liu, Tumour-targeting bacte- ria engineered to fight cancer, Nat. Rev. Cancer 18 (2018) 727-743, doi:10.1038/s41568-018-0070-z.

[23] H. Shen, N. Aggarwal, K.S. Wun, Y.S. Lee, I.Y. Hwang, M.W. Chang, Engineered microbial systems for advanced drug delivery, Adv. Drug Deliv. Rev.187 (2022) 114364, doi:10.1016/j.addr.2022.114364.

[24] I. Tanniche, B. Behkam, Engineered live bacteria as disease detection and diagnosis tools, J. Biol. Eng. 17 (2023) 65, doi:10.1186/s13036-023-00379-z.

[25] K. Kim, M.J. Kang, B.K. Cho, Systems and synthetic biology-driven engi- neering of live bacterial therapeutics, Front. Bioeng. Biotechnol. 11 (2023), doi:10.3389/fbioe.2023.1267378.

[26] K. Han, J. Xu, F. Xie, J. Crowther, J.J. Moon, Engineering Strategies to Modu- late the Gut Microbiome and Immune System, J. Immunol. 212 (2024) 208-215, doi:10.4049/jimmunol.2300480.

[27] C.M. Robinson, N.E. Short, D.T. Riglar, Achieving spatially precise diagnosis and therapy in the mammalian gut using synthetic microbial gene circuits, Front. Bio- eng. Biotechnol. 10 (2022), doi:10.3389/fbioe.2022.959441.

[28] Z. Zuo, F. Zhao, Gut microbiota-targeted interventions: from conven- tional approaches to genetic engineering, Sci. Bull. 68 (2023) 1231-1234, doi:10.1016/j.scib.2023.05.018.

[29] Y. Liu, W. Yu, Q. Wang, Z. Cao, J. Li, Artificially engineered bacteria to treat gastrointestinal disease and cancer, Drug Discov. Today 28 (2023) 103667, doi:10.1016/j.drudis.2023.103667.

[30] Z. Chen, W. Jin, A. Hoover, Y. Chao, Y. Ma, Decoding the microbiome: advances in genetic manipulation for gut bacteria, Trends. Microbiol. 31 (2023) 1143-1161, doi:10.1016/j.tim.2023.05.007.

[31] Y. Liu, Z. Zhu, L. Jiang, Programming therapeutic probiotics by self-tunable sense-and-respond genetic circuits, Trends. Microbiol. 31 (2023) 1099-1101, doi:10.1016/j.tim.2023.08.001.

[32] B.A. Stefanov, M. Fussenegger, Biomarker-driven feedback control of synthetic biol- ogy systems for next-generation personalized medicine, Front. Bioeng. Biotechnol. 10 (2022), doi:10.3389/fbioe.2022.986210.

[33] D.T. Riglar, P.A. Silver, Engineering bacteria for diagnostic and therapeutic appli- cations, Nat. Rev. Microbiol. 16 (2018) 214-225, doi:10.1038/nrmicro.2017.172.

[34] D.B. Pedrolli, N.V. Ribeiro, P.N. Squizato, V.N. de Jesus, D.A. Cozetto, R.B. Tuma, A. Gracindo, M.B. Cesar, P.J.C. Freire, A.F.M. da Costa, M.R.C.R. Lins, G.G. Correa, M.O. Cerri, Engineering Microbial Living Therapeutics: The Synthetic Biology Tool- box, Trends Biotechnol. 37 (2019) 100-115, doi:10.1016/j.tibtech.2018.09.005.

[35] S. Shigemori, T. Shimosato, Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Dis- eases, Front. Immunol. 8 (2017), doi:10.3389/fimmu.2017.00022.

[36] Z.J.S. Mays, N.U. Nair, Synthetic biology in probiotic lactic acid bacteria: At the frontier of living therapeutics, Curr. Opin. Biotechnol. 53 (2018) 224-231, doi:10.1016/j.copbio.2018.01.028.

[37] L. Steidler, W. Hans, L. Schotte, S. Neirynck, F. Obermeier, W. Falk, W. Fiers, E. Re- maut, Treatment of murine colitis by Lactococcus lactis secreting interleukin-10, Science (1979) 289 (2000) 1352-1355, doi:10.1126/science.289.5483.1352.

[38] L. Schotte, L. Steidler, J. Vandekerckhove, E. Remaut, Secretion of biologically active murine interleukin-10 by Lactococcus lactis, Enzyme Microb. Technol. 27 (2000) 761-765, doi:10.1016/s0141-0229(00)00297-0.

[39] L. Steidler, S. Neirynck, N. Huyghebaert, V. Snoeck, A. Vermeire, B. Goddeeris, E. Cox, J.P. Remon, E. Remaut, Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10, Nat. Biotechnol. 21 (2003) 785-789, doi:10.1038/nbt840.

[40] H. Braat, P. Rottiers, D.W. Hommes, N. Huyghebaert, E. Remaut, J.P. Remon, S.J. van Deventer, S. Neirynck, M.P. Peppelenbosch, L. Steidler, A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease, Clin. Gas- troenterol. Hepatol. 4 (2006) 754-759, doi:10.1016/j.cgh.2006.03.028.

[41] M.L. Hanson, J.A. Hixon, W. Li, B.K. Felber, M.R. Anver, C.A. Stewart, B. M. Janelsins, S.K. Datta, W. Shen, M.H. McLean, S.K. Durum, Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice, Gastroenterology 146 (2014) 210-221 e213, doi:10.1053/j.gastro.2013.09.060.

[42] U. Sonnenborn, Escherichia coli strain Nissle 1917 —from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties, FEMS Microbiol. Lett. 363 (2016) fnw212, doi:10.1093/femsle/fnw212.

[43] F. Ba, Y. Zhang, X. Ji, W.-Q. Liu, S. Ling, J. Li, Expanding the toolbox of probi- otic Escherichia coli Nissle 1917 for synthetic biology, Biotechnol. J. 19 (2024) 2300327, doi:10.1002/biot.202300327.

[44] M. Schultz, Clinical use of E. coli Nissle 1917 in inflammatory bowel disease, In- flamm. Bowel Dis. 14 (2008) 1012-1018, doi:10.1002/ibd.20377.

[45] U. Sonnenborn, J. Schulze, The non-pathogenic Escherichia coli strain Nissle 1917-features of a versatile probiotic, Microb. Ecol. Health Dis. 21 (2009) 122-158, doi:10.3109/08910600903444267.

[46] M. Schlee, J. Wehkamp, A. Altenhoefer, T.A. Oelschlaeger, E.F. Stange, K. Feller- mann, Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin, Infect. Immun. 75 (2007) 2399-2407, doi:10.1128/iai.01563-06.

[47] M. Sassone-Corsi, S.-P. Nuccio, H. Liu, D. Hernandez, C.T. Vu, A.A. Takahashi, R.A. Edwards, M. Raffatellu, Microcins mediate competition among Enterobacteri- aceae in the inflamed gut, Nature 540 (2016) 280-283, doi:10.1038/nature20557.

[48] R. Gardlik, R. Palffy, P. Celec, Recombinant probiotic therapy in experimental col- itis in mice, Folia Biol.-Prague 58 (2012) 238-245.

[49] B. Zhang, Y. Liu, X. Lan, X. Xu, X. Zhang, X. Li, Y. Zhao, G. Li, C. Du, S. Lu, H. Wang, Oral Escherichia coli expressing IL-35 meliorates experimental colitis in mice, J. Transl. Med. 16 (2018) 71, doi:10.1186/s12967-018-1441-7.

[50] S.O. Adegbola, K. Sahnan, J. Warusavitarne, A. Hart, Tozer Anti-TNF Therapy in Crohn’s Disease, Int. J. Mol. Sci. DOI (2018) 19, doi:10.3390/ijms19082244.

[51] K. Papamichael, W. Afif, D. Drobne, M.C. Dubinsky, M. Ferrante, P.M. Irving, N. Kamperidis, T. Kobayashi, P.G. Kotze, J. Lambert, N.M. Noor, X. Roblin, G. Roda, N. Vande Casteele, A.J. Yarur, N. Arebi, S. Danese, S. Paul, W.J. Sandborn, S. Ver- meire, A.S. Cheifetz, L. Peyrin-Biroulet, Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives, Lancet Gas- troenterol. Hepatol 7 (2022) 171-185, doi:10.1016/S2468-1253(21)00223-5.

[52] D.C. Baumgart, C.Le Berre, Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease, N. Engl. J. Med. 385 (2021) 1302-1315, doi:10.1056/NEJMra1907607.

[53] M. Friedrich, M. Pohin, F. Powrie, Cytokine Networks in the Pathophys- iology of Inflammatory Bowel Disease, Immunity. 50 (2019) 992-1006, doi:10.1016/j.immuni.2019.03.017.

[54] A. Tursi, G. Mocci, R. Lorenzetti, L. Allegretta, G. Brandimarte, C. Cassieri, R. Colucci, A. De Medici, R. Faggiani, A. Ferronato, S. Fiorella, G. Forti, M. Franceschi, S. Gallina, G. Giorgetti, G. Grasso, T. Larussa, F. Luzza, A. Penna, R. Pica, S. Piergallini, S. Porciello, G. Pranzo, S. Rodino’, S. Scorza, L. Sebkova, C. Zampaletta, W. Elisei, M. Picchio, Long-term real-life efficacy and safety of inflix- imab and adalimumab in the treatment of inflammatory bowel diseases outpatients, Eur. J. Gastroenterol. Hepatol. 33 (2021), doi:10.1097/MEG.0000000000002087.

[55] B. Ungar, I. Levy, Y. Yavne, M. Yavzori, O. Picard, E. Fudim, R. Loebstein, Y. Chow- ers, R. Eliakim, U. Kopylov, S. Ben-Horin, Optimizing Anti-TNF- 𝛼 Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Pa- tients With Inflammatory Bowel Diseases, Clin. Gastroenterol. Hepatol. 14 (2016) 550-557 e552, doi:10.1016/j.cgh.2015.10.025.

[56] S. Singh, M.H. Murad, M. Fumery, R. Sedano, V. Jairath, R. Panaccione, W.J. Sand- born, C. Ma, Comparative efficacy and safety of biologic therapies for moderate-to- severe Crohn’s disease: a systematic review and network meta-analysis, Lancet Gas- troenterol. Hepatol. 6 (2021) 1002-1014, doi:10.1016/S2468-1253(21)00312-5.

[57] A.S. Greenberg, D. Avila, M. Hughes, A. Hughes, E.C. McKinney, M.F. Fla- jnik, A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks, Nature 374 (1995) 168-173, doi:10.1038/374168a0.

[58] C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, E.B. Songa, N. Bendahman, R. Hamers, Naturally occurring antibodies devoid of light chains, Nature 363 (1993) 446-448, doi:10.1038/363446a0.

[59] K. Coppieters, T. Dreier, K. Silence, H. de Haard, M. Lauwereys, P. Casteels, E. Beir- naert, H. Jonckheere, C. Van de Wiele, L. Staelens, J. Hostens, H. Revets, E. Remaut, D. Elewaut, P. Rottiers, Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis, Arthritis Rheum. 54 (2006) 1856-1866, doi:10.1002/art.21827.

[60] E.R. Verhaar, A.W. Woodham, H.L. Ploegh, Nanobodies in cancer, Semin. Immunol 52 (2021) 101425, doi:10.1016/j.smim.2020.101425.

[61] K. Vandenbroucke, H. de Haard, E. Beirnaert, T. Dreier, M. Lauwereys, L. Huyck, J. Van Huysse, P. Demetter, L. Steidler, E. Remaut, C. Cuvelier, P. Rottiers, Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis, Mucosal. Immunol. 3 (2010) 49-56, doi:10.1038/mi.2009.116.

[62] J.P. Lynch, C. González-Prieto, A.Z. Reeves, S. Bae, U. Powale, N.P. Godbole, J. M. Tremblay, F.I. Schmidt, H.L. Ploegh, V. Kansra, J.N. Glickman, J.M. Leong, C.B. Shoemaker, W.S. Garrett, C.F. Lesser, Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut, Cell Host. Microbe 31 (2023) 634-649 e638, doi:10.1016/j.chom.2023.03.007.

[63] C. Schnoeller, S. Rausch, S. Pillai, A. Avagyan, B.M. Wittig, C. Loddenkem- per, A. Hamann, E. Hamelmann, R. Lucius, S. Hartmann, A helminth im- munomodulator reduces allergic and inflammatory responses by induction of IL-10- producing macrophages, J. Immunol. 180 (2008) 4265-4272, doi:10.4049/jim- munol.180.6.4265.

[64] C. Klotz, T. Ziegler, A.S. Figueiredo, S. Rausch, M.R. Hepworth, N. Obsivac, C. Sers, R. Lang, P. Hammerstein, R. Lucius, S. Hartmann, A helminth immunomodula- tor exploits host signaling events to regulate cytokine production in macrophages, PLoS. Pathog. 7 (2011) e1001248, doi:10.1371/journal.ppat.1001248.

[65] R.A. Whelan, S. Rausch, F. Ebner, D. Günzel, J.F. Richter, N.A. Hering, J.-D. Schulzke, A.A. Kühl, A. Keles, P. Janczyk, K. Nöckler, L.H. Wieler, S. Hart- mann, A Transgenic Probiotic Secreting a Parasite Immunomodulator for Site-Directed Treatment of Gut Inflammation, Mol. Ther. 22 (2014) 1730-1740, doi:10.1038/mt.2014.125.

[66] L. Wang, H. Xie, L. Xu, Q. Liao, S. Wan, Z. Yu, D. Lin, B. Zhang, Z. Lv, Z. Wu, X. Sun rSj 16 Protects against DSS-Induced Colitis by Inhibiting the PPAR- 𝛼 Signal- ing Pathway, Theranostics. 7 (2017) 3446-3460, doi:10.7150/thno.20359.

[67] L. Wang, Y. Liao, R. Yang, Z. Zhu, L. Zhang, Z. Wu, X. Sun, An engineered probiotic secreting Sj16 ameliorates colitis via Ruminococcaceae/butyrate/retinoic acid axis, Bioeng. Transl. Med. 6 (2021) e10219, doi:10.1002/btm2.10219.

[68] K. Vandenbroucke, W. Hans, J. Van Huysse, S. Neirynck, P. Demetter, E. Remaut, P. Rottiers, L. Steidler, Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice, Gastroenterology 127 (2004) 502-513, doi:10.1053/j.gastro.2004.05.020.

[69] D. Taupin, D.K. Podolsky, Trefoil factors: initiators of mucosal healing, Nat. Rev. Mol. Cell Biol. 4 (2003) 721-732, doi:10.1038/nrm1203.

[70] B.G. Feagan, B.E. Sands, W.J. Sandborn, M. Germinaro, M. Vetter, J. Shao, S. Sheng, J. Johanns, J. Panés, A. Tkachev, D. Kalimullina, R. Petryka, M. Osipenko, N. Tsarynna, L. Bilianskyi, D. Kleczkowski, A. Yurkiv, M. Woynarowski, O. Abra- hamovych, O. Ivanishyn, G. Rydzewska, J. Kierkus, E. Petrova, O. Vasilevskaya, H. Afanasieva, C. Francesconi, J. Leszczyszyn, E. Bunkova, D. Platonov, O. Dat- senko, O. Gridnyev, I. Hospodarsky, L. Prystupa, M. Stanislavchuk, A. Per- shko, O. Shchukina, V. Simanenkov, O. Golovchenko, W. Holderman, J. Lasa, J. Begun, M. de Lourdes de Abreu Ferrari, P. Lopez, A. Obrezan, S. Farooq, F. Tiongco, A. Novillo, E. Tron, F. Macrae, R. Leong, L. Yukie Sassaki, C. Zalt- man, R. Kaiser Junior, A. Stallmach, J. Klaus, M. Martinez, A. Ruiz, R. Ab- dulkhakov, V. Sharma, L. Korman, J. Lord, B. Patel, T. Ritter, Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial, Lancet Gastroenterol. Hepatol 8 (2023) 307-320, doi:10.1016/S2468-1253(22)00427-7.

[71] P.G. Kotze, S. Vermeire, Upgrading therapeutic ambitions and treat- ment outcomes, Nat. Rev. Gastroenterol. Hepatol. 21 (2024) 84-85, doi:10.1038/s41575-023-00885-x.

[72] D. Silvio, S. Virginia, J. Vipul, P.-B. Laurent, The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment), Gut 71 (2022) 2380, doi:10.1136/gutjnl-2022-327025.

[73] Y.-Q. Wu, Z.-P. Zou, Y. Zhou, B.-C. Ye, Dual engineered bacteria improve in- flammatory bowel disease in mice, Appl. Microbiol. Biotechnol. 108 (2024) 333, doi:10.1007/s00253-024-13163-w.

[74] A. Lavelle, H. Sokol, Gut microbiota-derived metabolites as key actors in in- flammatory bowel disease, Nat. Rev. Gastroenterol. Hepatol. 17 (2020) 223-237, doi:10.1038/s41575-019-0258-z.

[75] A. Allison, C. Karine, S. Harry, Gut microbiota-derived metabolites as central regulators in metabolic disorders, Gut 70 (2021) 1174, doi:10.1136/gutjnl-2020-323071.

[76] J.C. Newman, E. Verdin, 𝛽-hydroxybutyrate: much more than a metabolite, Dia- betes Res. Clin. Pract. 106 (2014) 173-181, doi:10.1016/j.diabres.2014.08.009.

[77] Y. Kashiwaya, T. Takeshima, N. Mori, K. Nakashima, K. Clarke, R.L. Veech, d- 𝛽 -Hydroxybutyrate protects neurons in models of Alzheimer’s and Parkin- son’s disease, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5440-5444, doi:10.1073/pnas.97.10.5440.

[78] X. Yan, X.-Y. Liu, D. Zhang, Y.-D. Zhang, Z.-H. Li, X. Liu, F. Wu, G.-Q. Chen, Construction of a sustainable 3-hydroxybutyrate-producing probiotic Es- cherichia coli for treatment of colitis, Cell. Mol. Immunol. 18 (2021) 2344-2357, doi:10.1038/s41423-021-00760-2.

[79] I. Floris, V. Arnau Vich, B. Marc Jan, F. Jingyuan, G. Dirk, C.V. Marijn, M.S. Lieke, A. Rudi, F. Lude, M.v.D. Hendrik, W.F.T.S. Rinze, H. Curtis, D. Gerard, J.X. Ramnik, A.M.F. Eleonora, W. Cisca, Z. Alexandra, K.W. Rinse, Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease, Gut 67 (2018) 108, doi:10.1136/gutjnl-2016-312135.

[80] T. Baxter Nielson, W. Schmidt Alexander, A. Venkataraman, S.Kim Kwi, C. Wal- dron, M.Schmidt Thomas, Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers, mBio 10 (2019) 10.1128/mbio.02566-02518, doi:10.1128/mbio.02566-18.

[81] V. Eeckhaut, S. Maes, M. Steppe, I. Cleynen, V. De Preter, K. Machiels, R. Ducatelle, S. Vermeire, F. Van Immerseel, The butyrate producing Clostridium cluster IV genus Butyricicoccus has a decreased abundance in IBD stool samples and a comparative efficacy in TNBS models compared to currently available therapeutics: P-177, In- flamm. Bowel Dis. 17 (2011) S65-S66, doi:10.1097/00054725-201112002-00211.

[82] X. Gong, H. Geng, Y. Yang, S. Zhang, Z. He, Y. Fan, F. Yin, Z. Zhang, G.-Q. Chen, Metabolic engineering of commensal bacteria for gut butyrate deliv- ery and dissection of host-microbe interaction, Metab. Eng. 80 (2023) 94-106, doi:10.1016/j.ymben.2023.09.008.

[83] J. Wu, H. Huang, L. Wang, M. Gao, S. Meng, S. Zou, Y. Feng, Z. Feng, Z. Zhu, X. Cao, B. Li, G. Kang, A tailored series of engineered yeasts for the cell-dependent treatment of inflammatory bowel disease by rational butyrate supplementation, Gut. Microbes. 16 (2024) 2316575, doi:10.1080/19490976.2024.2316575.

[84] G. Wang, Y. Fan, G. Zhang, S. Cai, Y. Ma, L. Yang, Y. Wang, H. Yu, S. Qiao, X. Zeng, Microbiota-derived indoles alleviate intestinal inflammation and modulate microbiome by microbial cross-feeding, Microbiome 12 (2024) 59, doi:10.1186/s40168-024-01750-y.

[85] K. Atarashi, J. Nishimura, T. Shima, Y. Umesaki, M. Yamamoto, M. Onoue, H. Yagita, N. Ishii, R. Evans, K. Honda, K. Takeda, ATP drives lamina pro- pria T(H)17 cell differentiation, Nature 455 (2008) 808-812, doi:10.1038/na- ture07240.

[86] M. Idzko, D. Ferrari, H.K. Eltzschig, Nucleotide signalling during inflammation, Nature 509 (2014) 310-317, doi:10.1038/nature13085.

[87] G. Dijkstra, H. Moshage, H.M. Van Dullemen, A. De Jager-Krikken, A.T.M.G. Tie- bosch, J.H. Kleibeuker, P.L.M. Jansen, H. Van Goor, Expression of ni- tric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease, J. Pathol. 186 (1998) 416-421, doi:10.1002/(SICI)1096-9896(199812)186:4 < 416::AID-PATH201>3.0.CO;2-U.

[88] Y. Ma, J. Zhao, L. Cheng, C. Li, X. Yan, Z. Deng, Y. Zhang, J. Liang, C. Liu, M. Zhang, Versatile carbon dots with superoxide dismutase-like nanozyme activity and red fluorescence for inflammatory bowel disease therapeutics, Carbon. N. Y. 204 (2023) 526-537, doi:10.1016/j.carbon.2023.01.006.

[89] T. Zhang, J. Jiang, J. Liu, L. Xu, S. Duan, L. Sun, W. Zhao, F. Qian, MK 2 Is Required for Neutrophil-Derived ROS Production and Inflammatory Bowel Disease, Front. Med. 7 (2020) 207, doi:10.3389/fmed.2020.00207.

[90] M. Liu, S. Li, Q. Zhang, Z. Xu, J. Wang, H. Sun, Oral engineered Bifidobacterium longum expressing rhMnSOD to suppress experimental colitis, Int. Immunophar- macol. 57 (2018) 25-32, doi:10.1016/j.intimp.2018.02.004.

[91] J. Zhou, M. Li, Q. Chen, X. Li, L. Chen, Z. Dong, W. Zhu, Y. Yang, Z. Liu, Q. Chen, Programmable probiotics modulate inflammation and gut microbiota for inflam- matory bowel disease treatment after effective oral delivery, Nat. Commun. 13 (2022) 3432, doi:10.1038/s41467-022-31171-0.

[92] S. Shigemori, T. Watanabe, K. Kudoh, M. Ihara, S. Nigar, Y. Yamamoto, Y. Suda, T. Sato, H. Kitazawa, T. Shimosato, Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice, Microb. Cell Fact. 14 (2015) 189, doi:10.1186/s12934-015-0378-2.

[93] N.M. Breyner, C. Michon, C.S. de Sousa, P.B. Vilas Boas, F. Chain, V.A. Azevedo, P. Langella, J.M. Chatel, Microbial Anti-Inflammatory Molecule (MAM) from Fae- calibacterium prausnitzii Shows a Protective Effect on DNBS and DSS-Induced Col- itis Model in Mice through Inhibition of NF- 𝜅B Pathway, Front. Microbiol. 8 (2017) 114, doi:10.3389/fmicb.2017.00114.

[94] E. Quévrain, M.A. Maubert, C. Michon, F. Chain, R. Marquant, J. Tailhades, S. Miquel, L. Carlier, L.G. Bermúdez-Humarán, B. Pigneur, O. Lequin, P. Kharrat, G. Thomas, D. Rainteau, C. Aubry, N. Breyner, C. Afonso, S. Lavielle, J.P. Grill, G. Chassaing, J.M. Chatel, G. Trugnan, R. Xavier, P. Langella, H. Sokol, P. Sek- sik, Identification of an anti-inflammatory protein from Faecalibacterium praus- nitzii, a commensal bacterium deficient in Crohn’s disease, Gut 65 (2016) 415-425, doi:10.1136/gutjnl-2014-307649.

[95] P. Praveschotinunt, A.M. Duraj-Thatte, I. Gelfat, F. Bahl, D.B. Chou, N.S. Joshi, En- gineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut, Nat. Commun. 10 (2019) 5580, doi:10.1038/s41467-019-13336-6.

[96] Z.Z. Hamady, N. Scott, M.D. Farrar, J.P. Lodge, K.T. Holland, T. Whitehead, S.R. Carding, Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ova- tus, Gut 59 (2010) 461-469, doi:10.1136/gut.2008.176131.

[97] Z.Z. Hamady, N. Scott, M.D. Farrar, M. Wadhwa, P. Dilger, T.R. Whitehead, R. Thorpe, K.T. Holland, J.P. Lodge, S.R. Carding, Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-𝛽 1 under the control of dietary xylan 1, Inflamm. Bowel Dis. 17 (2011) 1925-1935, doi:10.1002/ibd. 21565.

[98] A. Miyoshi, E. Jamet, J. Commissaire, P. Renault, P. Langella, V. Azevedo, A xylose-inducible expression system for Lactococcus lactis, FEMS Microbiol. Lett. 239 (2004) 205-212, doi:10.1016/j.femsle.2004.08.018.

[99] S. del Carmen, A. de Moreno de LeBlanc, G. Perdigon, V. Bastos Pereira, A. Miyoshi, V. Azevedo, J.G. LeBlanc, Evaluation of the anti-inflammatory effect of milk fermented by a strain of IL-10-producing Lactococcus lactis using a murine model of Crohn’s disease, J. Mol. Microbiol. Biotechnol. 21 (2011) 138-146, doi:10.1159/000333830.

[100] T.-T. Fang, Z.-P. Zou, Y. Zhou, B.-C. Ye, Prebiotics-Controlled Disposable Engi- neered Bacteria for Intestinal Diseases, ACS Synth. Biol. 11 (2022) 3004-3014, doi:10.1021/acssynbio.2c00182.

[101] Z. Liu, J. Zhang, J. Jin, Z. Geng, Q. Qi, Q. Liang, Programming Bacteria With Light-Sensors and Applications in Synthetic Biology, Front. Microbiol. 9 (2018) 2692, doi:10.3389/fmicb.2018.02692.

[102] J. Fernandez-Rodriguez, F. Moser, M. Song, C.A. Voigt, Engineering RGB color vision into Escherichia coli, Nat. Chem. Biol. 13 (2017) 706-708, doi:10.1038/nchembio.2390.

[103] A. Levskaya, A.A. Chevalier, J.J. Tabor, Z.B. Simpson, L.A. Lavery, M. Levy, E.A. Davidson, A. Scouras, A.D. Ellington, E.M. Marcotte, C.A. Voigt, Synthetic biology: engineering Escherichia coli to see light, Nature 438 (2005) 441-442, doi:10.1038/nature04405.

[104] M. Cui, G. Pang, T. Zhang, T. Sun, L. Zhang, R. Kang, X. Xue, H. Pan, C. Yang, X. Zhang, J. Chang, J. Liu, S. Zhang, H. Wang, Optotheranostic Nanosystem with Phone Visual Diagnosis and Optogenetic Microbial Therapy for Ulcerative Colitis At-Home Care, ACS. Nano 15 (2021) 7040-7052, doi:10.1021/acsnano. 1c00135.

[105] M. Cui, T. Sun, S. Li, H. Pan, J. Liu, X. Zhang, L. Li, S. Li, C. Wei, C. Yu, C. Yang, N. Ma, B. Ma, S. Lu, J. Chang, W. Zhang, H. Wang, NIR light-responsive bacteria with live bio-glue coatings for precise colonization in the gut, Cell Rep. 36 (2021) 109690, doi:10.1016/j.celrep.2021.109690.

[106] R.W. Bourdeau, A. Lee-Gosselin, A. Lakshmanan, A. Farhadi, S.R. Kumar, S.P. Nety, M. G. Shapiro, Acoustic reporter genes for noninvasive imaging of microor- ganisms in mammalian hosts, Nature 553 (2018) 86-90, doi:10.1038/nature 25021.

[107] R.C. Hurt, M.T. Buss, M. Duan, K. Wong, M.Y. You, D.P. Sawyer, M.B. Swift, P. Dutka, P. Barturen-Larrea, D.R. Mittelstein, Z. Jin, M.H. Abedi, A. Farhadi, R. Deshpande, M.G. Shapiro, Genomically mined acoustic reporter genes for real- time in vivo monitoring of tumors and tumor-homing bacteria, Nat. Biotechnol. 41 (2023) 919-931, doi:10.1038/s41587-022-01581-y.

[108] M.H. Abedi, M.S. Yao, D.R. Mittelstein, A. Bar-Zion, M.B. Swift, A. Lee-Gosselin, P. Barturen-Larrea, M.T. Buss, M.G. Shapiro, Ultrasound-controllable engineered bacteria for cancer immunotherapy, Nat. Commun. 13 (2022) 1585, doi:10.1038/s41467-022-29065-2.

[109] Y. Chen, M. Du, Z. Yuan, Z. Chen, F. Yan, Spatiotemporal control of engineered bacteria to express interferon-𝛾 by focused ultrasound for tumor immunotherapy, Nat. Commun. 13 (2022) 4468, doi:10.1038/s41467-022-31932-x.

[110] P. Landry Brian, J. Tabor Jeffrey, Engineering Diagnostic and Therapeutic Gut Bacteria, Microbiol. Spectr. 5 (2017), doi:10.1128/microbiolspec.bad-0020-2017.

[111] T. Tanna, R. Ramachanderan, R.J. Platt, Engineered bacteria to report gut func- tion: technologies and implementation, Curr. Opin. Microbiol. 59 (2021) 24-33, doi:10.1016/j.mib.2020.07.014.

[112] M. Hicks, T.T. Bachmann, B. Wang, Synthetic Biology Enables Pro- grammable Cell-Based Biosensors, Chemphyschem. 21 (2020) 132-144, doi:10.1002/cphc.201900739.

[113] M.D. Levitt, J. Furne, J. Springfield, F. Suarez, E. DeMaster, Detoxification of hy- drogen sulfide and methanethiol in the cecal mucosa, J. Clin. Invest. 104 (1999) 1107-1114, doi:10.1172/jci7712.

[114] J. Furne, J. Springfield, T. Koenig, E. DeMaster, M.D. Levitt, Oxidation of hydrogen sulfide and methanethiol to thiosulfate by rat tissues: a special- ized function of the colonic mucosa, Biochem. Pharmacol. 62 (2001) 255-259, doi:10.1016/s0006-2952(01)00657-8.

[115] S.E. Winter, P. Thiennimitr, M.G. Winter, B.P. Butler, D.L. Huseby, R.W. Crawford, J. M. Russell, C.L. Bevins, L.G. Adams, R.M. Tsolis, J.R. Roth, A.J. Bäumler, Gut inflammation provides a respiratory electron acceptor for Salmonella, Nature 467 (2010) 426-429, doi:10.1038/nature09415.

[116] M. Hensel, A.P. Hinsley, T. Nikolaus, G. Sawers, B.C. Berks, The genetic basis of tetrathionate respiration in Salmonella typhimurium, Mol. Microbiol. 32 (1999) 275-287, doi:10.1046/j.1365-2958.1999.01345.x.

[117] D.T. Riglar, T.W. Giessen, M. Baym, S.J. Kerns, M.J. Niederhuber, R.T. Bronson, J.W. Kotula, G.K. Gerber, J.C. Way, P.A. Silver, Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation, Nat. Biotechnol. 35 (2017) 653-658, doi:10.1038/nbt.3879.

[118] M. Price-Carter, J. Tingey, T.A. Bobik, J.R. Roth, The alternative electron accep- tor tetrathionate supports B12-dependent anaerobic growth of Salmonella enterica serovar typhimurium on ethanolamine or 1,2-propanediol, J. Bacteriol. 183 (2001) 2463-2475, doi:10.1128/jb.183.8.2463-2475.2001.

[119] S.E. Winter, M.G. Winter, M.N. Xavier, P. Thiennimitr, V. Poon, A.M. Keestra, R. C. Laughlin, G. Gomez, J. Wu, S.D. Lawhon, I.E. Popova, S.J. Parikh, L.G. Adams, R.M. Tsolis, V.J. Stewart, A.J. Bäumler, Host-derived nitrate boosts growth of E. coli in the inflamed gut, Science (1979) 339 (2013) 708-711, doi:10.1126/sci- ence.1232467.

[120] K.N.M. Daeffler, J.D. Galley, R.U. Sheth, L.C. Ortiz-Velez, C.O. Bibb, N.F. Shroyer, R.A. Britton, J.J. Tabor, Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation, Mol. Syst. Biol. 13 (2017) 923, doi:10.15252/msb.20167416.

[121] H. Liu, K. Fan, H. Li, Q. Wang, Y. Yang, K. Li, Y. Xia, L. Xun, Synthetic Gene Circuits Enable Escherichia coli To Use Endogenous H2S as a Signaling Molecule for Quorum Sensing, ACS Synth. Biol. 8 (2019) 2113-2120, doi:10.1021/acssyn- bio.9b00210.

[122] M. Guslandi, Nitric oxide and inflammatory bowel diseases, Eur. J. Clin. Invest. 28 (1998) 904-907, doi:10.1046/j.1365-2362.1998.00377.x.

[123] D.M. McCafferty, Peroxynitrite and inflammatory bowel disease, Gut 46 (2000) 436-439, doi:10.1136/gut.46.3.436.

[124] F. Saijo, A.B. Milsom, N.S. Bryan, S.M. Bauer, T. Vowinkel, M. Ivanovic, C. Andry, D. N. Granger, J. Rodriguez, M. Feelisch, On the dynamics of nitrite, nitrate and other biomarkers of nitric oxide production in inflammatory bowel disease, Nitric Oxide-Biol. Chem. 22 (2010) 155-167, doi:10.1016/j.niox.2009.11.009.

[125] H. Kimura, S. Miura, T. Shigematsu, N. Ohkubo, Y. Tsuzuki, I. Kurose, H. Higuchi, Y. Akiba, R. Hokari, M. Hirokawa, H. Serizawa, H. Ishii, Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of pa- tients with active ulcerative colitis and Crohn’s disease, Dig. Dis. Sci. 42 (1997) 1047-1054, doi:10.1023/a:1018849405922.

[126] E.J. Archer, A.B. Robinson, G.M. Süel, Engineered E. coli that detect and respond to gut inflammation through nitric oxide sensing, ACS Synth. Biol. 1 (2012) 451-457, doi:10.1021/sb3000595.

[127] S.-G. Woo, S.-J. Moon, S.K. Kim, T.H. Kim, H.S. Lim, G.-H. Yeon, B.H. Sung, C.-H. Lee, S.-G. Lee, J.H. Hwang, D.-H. Lee, A designed whole-cell biosensor for live diagnosis of gut inflammation through nitrate sensing, Biosens. Bioelectron. 168 (2020) 112523, doi:10.1016/j.bios.2020.112523.

[128] S. Flynn, S. Eisenstein, Inflammatory Bowel Disease Presentation and Diagnosis, Surg. Clin.-North Am. 99 (2019) 1051-1062, doi:10.1016/j.suc.2019.08.001.

[129] Z.-P. Zou, Y. Yang, J. Wang, Y. Zhou, B.-C. Ye, Coupling split-lux cassette with a toggle switch in bacteria for ultrasensitive blood markers detection in feces and urine, Biosens. Bioelectron. 214 (2022) 114520, doi:10.1016/j.bios.2022.114520.

[130] I.M. Cartwright, A.S. Dowdell, J.M. Lanis, K.R. Brink, A. Mu, R.E. Kostelecky, R.E.M. Schaefer, N. Welch, J.C. Onyiah, C.H.T. Hall, M.E. Gerich, J.J. Tabor, S.P. Colgan, Mucosal acidosis elicits a unique molecular signature in epithelia and intestinal tissue mediated by GPR31-induced CREB phosphorylation, Proc. Natl. Acad. Sci. U. S. A. 118 (2021) e2023871118, doi:10.1073/pnas.2023871118.

[131] J. Almina, B. Latifa, F.W. Erwin, T. Herbert, E.A. Timon, Calpro- tectin: from biomarker to biological function, Gut 70 (2021) 1978, doi:10.1136/gutjnl-2021-324855.

[132] B.E. Sands, Biomarkers of Inflammation in Inflammatory Bowel Disease, Gastroen- terology 149 (2015) 1275-1285 e1272, doi:10.1053/j.gastro.2015.07.003.

[133] G.R. Lichtenstein, S.B. Hanauer, W.J. Sandborn, Management of Crohn’s dis- ease in adults, Am. J. Gastroenterol. 104 (2009) 465-483 quiz 464, 484, doi:10.1038/ajg.2008.168.

[134] J.Y. Xia, C. Hepler, P. Tran, N.J. Waldeck, J. Bass, A. Prindle, Engineered calprotectin-sensing probiotics for IBD surveillance in humans, Proc. Natl. Acad. Sci. U. S. A. 120 (2023) e2221121120, doi:10.1073/pnas.2221121120.

[135] Z. Duolong, G. Jeffrey, P. Jason, M. Elena, J.T. Jeffrey, A.B. Robert, Microbial biosensor for sensing and treatment of intestinal inflammation, bioRxiv. (2023) 550106 2023.2007.2021, doi:10.1101/2023.07.21.550106.

[136] M.B. Brophy, J.A. Hayden, E.M. Nolan, Calcium ion gradients modulate the zinc affinity and antibacterial activity of human calprotectin, J. Am. Chem. Soc. 134 (2012) 18089-18100, doi:10.1021/ja307974e.

[137] T.G. Nakashige, E.M. Zygiel, C.L. Drennan, E.M. Nolan, Nickel Sequestration by the Host-Defense Protein Human Calprotectin, J. Am. Chem. Soc. 139 (2017) 8828-8836, doi:10.1021/jacs.7b01212.

[138] S.E. Gabriel, J.D. Helmann, Contributions of Zur-controlled ribosomal proteins to growth under zinc starvation conditions, J. Bacteriol. 191 (2009) 6116-6122, doi:10.1128/jb.00802-09.

[139] J.Z. Liu, S. Jellbauer, A.J. Poe, V. Ton, M. Pesciaroli, T.E. Kehl-Fie, N.A. Restrepo, M. P. Hosking, R.A. Edwards, A. Battistoni, P. Pasquali, T.E. Lane, W.J. Chazin, T. Vogl, J. Roth, E.P. Skaar, M. Raffatellu, Zinc sequestration by the neutrophil protein calprotectin enhances Salmonella growth in the inflamed gut, Cell Host. Microbe 11 (2012) 227-239, doi:10.1016/j.chom.2012.01.017.

[140] B.A. Gilston, S. Wang, M.D. Marcus, M.A. Canalizo-Hernández, E.P. Swindell, Y. Xue, A. Mondragón, T.V. O’Halloran, Structural and mechanistic basis of zinc regulation across the E. coli Zur regulon, PLoS. Biol. 12 (2014) e1001987, doi:10.1371/journal.pbio.1001987.

[141] M. Mimee, P. Nadeau, A. Hayward, S. Carim, S. Flanagan, L. Jerger, J. Collins, S. McDonnell, R. Swartwout, R.J. Citorik, V. Bulovi ć, R. Langer, G. Traverso, A.P. Chandrakasan, T.K. Lu, An ingestible bacterial-electronic system to moni- tor gastrointestinal health, Science (1979) 360 (2018) 915-918, doi:10.1126/sci- ence.aas9315.

[142] M.E. Inda-Webb, M. Jimenez, Q. Liu, N.V. Phan, J. Ahn, C. Steiger, A. Went- worth, A. Riaz, T. Zirtiloglu, K. Wong, K. Ishida, N. Fabian, J. Jenkins, J. Ku- osmanen, W. Madani, R. McNally, Y. Lai, A. Hayward, M. Mimee, P. Nadeau, A.P. Chandrakasan, G. Traverso, R.T. Yazicigil, T.K. Lu, Sub-1.4 cm3 capsule for detecting labile inflammatory biomarkers in situ, Nature 620 (2023) 386-392, doi:10.1038/s41586-023-06369-x.

[143] R.U. Sheth, H.H. Wang, DNA-based memory devices for recording cellular events, Nat. Rev. Genet. 19 (2018) 718-732, doi:10.1038/s41576-018-0052-8.

[144] Z.-P. Zou, B.-C. Ye, Long-Term Rewritable Report and Recording of Environmental Stimuli in Engineered Bacterial Populations, ACS Synth. Biol. 9 (2020) 2440-2449, doi:10.1021/acssynbio.0c00193.

[145] F. Schmidt, M.Y. Cherepkova, R.J. Platt, Transcriptional recording by CRISPR spacer acquisition from RNA, Nature 562 (2018) 380-385, doi:10.1038/s41586-018-0569-1.

[146] T. Tanna, F. Schmidt, M.Y. Cherepkova, M. Okoniewski, R.J. Platt, Record- ing transcriptional histories using Record-seq, Nat. Protoc. 15 (2020) 513-539, doi:10.1038/s41596-019-0253-4.

[147] F. Schmidt, J. Zimmermann, T. Tanna, R. Farouni, T. Conway, A.J. Macpher- son, R.J. Platt, Noninvasive assessment of gut function using transcriptional recording sentinel cells, Science (1979) 376 (2022) eabm6038, doi:10.1126/sci- ence.abm6038.

[148] B. Benbouziane, P. Ribelles, C. Aubry, R. Martin, P. Kharrat, A. Riazi, P. Lan- gella, L.G. Bermúdez-Humarán, Development of a Stress-Inducible Controlled Ex- pression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces, J. Biotechnol. 168 (2013) 120-129, doi:10.1016/j.jbiotec.2013.04.019.

[149] J.D. Palmer, E. Piattelli, B.A. McCormick, M.W. Silby, C.J. Brigham, V. Bucci, Engineered Probiotic for the Inhibition of Salmonella via Tetrathionate-Induced Production of Microcin H47, ACS Infect. Dis. 4 (2018) 39-45, doi:10.1021/acsin- fecdis.7b00114.

[150] K.J. Chua, H. Ling, I.Y. Hwang, H.L. Lee, J.C. March, Y.S. Lee, M.W. Chang, An Engineered Probiotic Produces a Type III Interferon IFNL1 and Reduces Inflamma- tions in in vitro Inflammatory Bowel Disease Models, ACS Biomater. Sci. Eng. 9 (2023) 5123-5135, doi:10.1021/acsbiomaterials.2c00202.

[151] R. McKay, M. Ghodasra, J. Schardt, D. Quan, A.E. Pottash, W. Shang, S.M. Jay, G.F. Payne, M.W. Chang, J.C. March, W.E. Bentley, A platform of geneti- cally engineered bacteria as vehicles for localized delivery of therapeutics: To- ward applications for Crohn’s disease, Bioeng. Transl. Med. 3 (2018) 209-221, doi:10.1002/btm2.10113.

[152] Z.-P. Zou, Y. Du, T.-T. Fang, Y. Zhou, B.-C. Ye, Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in mice, Cell Host. Microbe 31 (2023) 199-212 e195, doi:10.1016/j.chom.2022.12.004.

[153] B.M. Scott, C. Gutiérrez-Vázquez, L.M. Sanmarco, J.A. da Silva Pereira, Z. Li, A. Plasencia, P. Hewson, L.M. Cox, M. O’Brien, S.K. Chen, P.M. Moraes-Vieira, B.S.W. Chang, S.G. Peisajovich, F.J. Quintana, Self-tunable engineered yeast probi- otics for the treatment of inflammatory bowel disease, Nat. Med. 27 (2021) 1212-1222, doi:10.1038/s41591-021-01390-x.

[154] X.-G. Wang, Z.-P. Zou, Y. Du, B.-C. Ye, Y. Zhou, Construction of an Engi- neered Escherichia coli with Efficient Chemotactic and Metabolizing Ability to- ward Tetrathionate, ACS Synth. Biol. 12 (2023) 3414-3423, doi:10.1021/acssyn- bio.3c00445.

[155] M. Laviña, C. Gaggero, F. Moreno, Microcin H47, a chromosome-encoded microcin antibiotic of Escherichia coli, J. Bacteriol. 172 (1990) 6585-6588, doi:10.1128/jb.172.11.6585-6588.1990.

[156] Z.-P. Zou, Y.-H. Fan, Y. Du, T.-T. Fang, W. Du, Y. Zhou, B.-C. Ye, Protocol for engi- neering E. coli Nissle 1917 to diagnose, record, and ameliorate inflammatory bowel disease in mice, STAR. Protoc. 4 (2023) 102254, doi:10.1016/j.xpro.2023.102254.

[157] C.R. Gurbatri, G.A. Radford, L. Vrbanac, J. Im, E.M. Thomas, C. Coker, S.R. Taylor, Y. Jang, A. Sivan, K. Rhee, A.A. Saleh, T. Chien, F. Zandkarimi, I. Lia, T.R.M. Lan- nagan, T. Wang, J.A. Wright, H. Kobayashi, J.Q. Ng, M. Lawrence, T. Sammour, M. Thomas, M. Lewis, L. Papanicolas, J. Perry, T. Fitzsimmons, P. Kaazan, A. Lim, A.M. Stavropoulos, D.A. Gouskos, J. Marker, C. Ostroff, G. Rogers, N. Arpaia, D.L. Worthley, S.L. Woods, T. Danino, Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia, Nat. Commun. 15 (2024) 646, doi:10.1038/s41467-024-44776-4.

[158] S.K. Kim, R.B. Guevarra, Y.T. Kim, J. Kwon, H. Kim, J.H. Cho, H.B. Kim, J.H. Lee, Role of Probiotics in Human Gut Microbiome-Associated Diseases, J. Microbiol. Biotechnol. 29 (2019) 1335-1340, doi:10.4014/jmb.1906.06064.

[159] R. Tojo, A. Suárez, M.G. Clemente, C.G. de los Reyes-Gavilán, A. Margolles, M. Gueimonde, P. Ruas-Madiedo, Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis, World J. Gastroenterol. 20 (2014) 15163-15176, doi:10.3748/wjg.v20.i41.15163.

[160] M.K. Yadav, I. Kumari, B. Singh, K.K. Sharma, S.K. Tiwari, Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics, Appl. Microbiol. Biotech- nol 106 (2022) 505-521, doi:10.1007/s00253-021-11646-8.

[161] H. Chen, P. Lei, H. Ji, Q. Yang, B. Peng, J. Ma, Y. Fang, L. Qu, H. Li, W. Wu, L. Jin, D. Sun, Advances in Escherichia coli Nissle 1917 as a customizable drug delivery system for disease treatment and diagnosis strategies, Mater. Today Bio 18 (2023) 100543, doi:10.1016/j.mtbio.2023.100543.

[162] M. Mimee, Alex C. Tucker, Christopher A. Voigt, Timothy K. Lu, Program- ming a Human Commensal Bacterium, Bacteroides thetaiotaomicron, to Sense and Respond to Stimuli in the Murine Gut MicrobiotaK, Cell Syst. 2 (2016) 214, doi:10.1016/j.cels.2016.03.007.

[163] B. Lim, M. Zimmermann, N.A. Barry, A.L. Goodman, Engineered Regulatory Sys- tems Modulate Gene Expression of Human Commensals in the Gut, Cell 169 (2017) 547-558 e515, doi:10.1016/j.cell.2017.03.045.

[164] W.R. Whitaker, E.S. Shepherd, J.L. Sonnenburg, Tunable Expression Tools Enable Single-Cell Strain Distinction in the Gut Microbiome, Cell 169 (2017) 538-546 e512, doi:10.1016/j.cell.2017.03.041.

[165] B.J. Russell, S.D. Brown, N. Siguenza, I. Mai, A.R. Saran, A. Lingaraju, E.S. Maissy, A. C. Dantas Machado, A.F.M. Pinto, C. Sanchez, L.-A. Rossitto, Y. Miyamoto, R.A. Richter, S.B. Ho, L. Eckmann, J. Hasty, D.J. Gonzalez, A. Saghatelian, R. Knight, A. Zarrinpar, Intestinal transgene delivery with native E. coli chas- sis allows persistent physiological changes, Cell 185 (2022) 3263-3277 e3215, doi:10.1016/j.cell.2022.06.050.

[166] B.J. Arnold, I.T. Huang, W.P. Hanage, Horizontal gene transfer and adap- tive evolution in bacteria, Nat. Rev. Microbiol. 20 (2022) 206-218, doi:10.1038/s41579-021-00650-4.

[167] L. Boto, Horizontal gene transfer in evolution: facts and challenges, Proc. Biol. Sci. 277 (2010) 819-827, doi:10.1098/rspb.2009.1679.

[168] C. Munck, R.U. Sheth, D.E. Freedberg, H.H. Wang, Recording mobile DNA in the gut microbiota using an Escherichia coli CRISPR-Cas spacer acquisition platform, Nat. Commun. 11 (2020) 95, doi:10.1038/s41467-019-14012-5.

[169] J.R. Rubens, G. Selvaggio, T.K. Lu, Synthetic mixed-signal computation in living cells, Nat. Commun. 7 (2016) 11658, doi:10.1038/ncomms11658.

[170] T. Chien, T. Harimoto, B. Kepecs, K. Gray, C. Coker, N. Hou, K. Pu, T. Azad, A. Nolasco, M. Pavlicova, T. Danino, Enhancing the tropism of bacteria via genetically programmed biosensors, Nat. Biomed. Eng 6 (2022) 94-104, doi:10.1038/s41551-021-00772-3.

[171] Y. Gao, L. Wang, B. Wang, Customizing cellular signal processing by synthetic multi-level regulatory circuits, Nat. Commun. 14 (2023) 8415, doi:10.1038/s41467-023-44256-1.

[172] T.Y.H. Ho, A. Shao, Z. Lu, H. Savilahti, F. Menolascina, L. Wang, N. Dalchau, B. Wang, A systematic approach to inserting split inteins for Boolean logic gate engineering and basal activity reduction, Nat. Commun. 12 (2021) 2200, doi:10.1038/s41467-021-22404-9.

[173] B. Wang, R.I. Kitney, N. Joly, M. Buck, Engineering modular and orthogonal genetic logic gates for robust digital-like synthetic biology, Nat. Commun. 2 (2011) 508, doi:10.1038/ncomms1516.

[174] J.J. Jaekel, D. Schweingruber, V. Cheras, J. Doshi, Y. Benenson, Multi-input bio- computer gene circuits for therapeutic application, Curr. Opin. Syst. Biol. 28 (2021) 100371, doi:10.1016/j.coisb.2021.100371.

[175] N.M. Liana, S.S. Andrey, P. Ayush, M.M. Richard, N.G. Leopold, Engineer- ing Logical Inflammation Sensing Circuit for Gut Modulation, bioRxiv. (2020) 2020.2011.2010. 377085., doi:10.1101/2020.11.10.377085.

[176] H.-J. Chang, P. Mayonove, A. Zavala, A. De Visch, P. Minard, M. Cohen-Gonsaud, J. Bonnet, A Modular Receptor Platform To Expand the Sensing Repertoire of Bac- teria, ACS Synth. Biol. 7 (2018) 166-175, doi:10.1021/acssynbio.7b00266.

[177] H.-J. Chang, A. Zúñiga, I. Conejero, P.L. Voyvodic, J. Gracy, E. Fajardo-Ruiz, M. Cohen-Gonsaud, G. Cambray, G.-P. Pageaux, M. Meszaros, L. Meu- nier, J. Bonnet, Programmable receptors enable bacterial biosensors to detect pathological biomarkers in clinical samples, Nat. Commun. 12 (2021) 5216, doi:10.1038/s41467-021-25538-y.

[178] N. Ding, S. Zhou, Y. Deng, Transcription-Factor-based Biosensor Engineering for Applications in Synthetic Biology, ACS Synth. Biol. 10 (2021) 911-922, doi:10.1021/acssynbio.0c00252.

[179] B. Wang, M. Barahona, M. Buck, A modular cell-based biosensor using engi- neered genetic logic circuits to detect and integrate multiple environmental signals, Biosens. Bioelectron. 40 (2013) 368-376, doi:10.1016/j.bios.2012.08.011.

[180] X. Wang, N. Zhou, B. Wang, Bacterial synthetic biology: tools for novel drug discovery, Expert. Opin. Drug Discov. 18 (2023) 1087-1097, doi:10.1080/17460441.2023.2239704.

[181] X. Wan, F. Volpetti, E. Petrova, C. French, S.J. Maerkl, B. Wang, Cascaded amplify- ing circuits enable ultrasensitive cellular sensors for toxic metals, Nat. Chem. Biol. 15 (2019) 540-548, doi:10.1038/s41589-019-0244-3.

[182] M.T. Nelson, M.R. Charbonneau, H.G. Coia, M.J. Castillo, C. Holt, E.S. Greenwood, P.J. Robinson, E.A. Merrill, D. Lubkowicz, C.A. Mauzy, Characterization of an engi- neered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip, Nat. Commun. 12 (2021) 2805, doi:10.1038/s41467-021-23072-5.

[183] Z. Li, Y. Wang, J. Liu, P. Rawding, J. Bu, S. Hong, Q. Hu, Chemically and Biologi- cally Engineered Bacteria-Based Delivery Systems for Emerging Diagnosis and Ad- vanced Therapy, Adv. Mater. 33 (2021) 2102580, doi:10.1002/adma.202102580.

[184] S. Lin, F. Wu, Y. Zhang, H. Chen, H. Guo, Y. Chen, J. Liu, Surface-modified bacte- ria: synthesis, functionalization and biomedical applications, Chem. Soc. Rev. 52 (2023) 6617-6643, doi:10.1039/D3CS00369H.

[185] S. Yu, H. Sun, Y. Li, S. Wei, J. Xu, J. Liu, Hydrogels as promising platforms for engi- neered living bacteria-mediated therapeutic systems, Mater. Today Bio 16 (2022) 100435, doi:10.1016/j.mtbio.2022.100435.